Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Journal Scan / Research · March 17, 2022

Predicting Response to ICI Therapy Using ctDNA in Metastatic Renal Cell Carcinoma

International Journal of Urology: Official Journal of the Japanese Urological Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Urology: Official Journal of the Japanese Urological Association
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma
Int. J. Urol. 2022 Feb 19;[EPub Ahead of Print], Y Koh, K Nakano, K Katayama, G Yamamichi, S Yumiba, E Tomiyama, M Matsushita, Y Hayashi, Y Yamamoto, T Kato, K Hatano, A Kawashima, T Ujike, R Imamura, R Yamaguchi, S Imoto, Y Shiotsu, N Nonomura, M Uemura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading